Targeted treatments for vascular malformations: current state of the art
Journal of Thrombosis and Haemostasis · 2024-11 · 22 (11) · 2961-2975
DOI: 10.1016/j.jtha.2024.07.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-11. Verfasst von Emmanuel Seront und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium.…. Hauptthemen laut MEDLINE: Vascular Malformations, Molecular Targeted Therapy, Signal Transduction. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: King Baudouin Foundation, WELBIO, FRS-FNRS.
Abstract (Originalsprache)
Vascular malformations, which arise from anomalies in angiogenesis, encompass capillary, lymphatic, venous, arteriovenous, and mixed malformations, each affecting specific vessel types. Historically, therapeutic options such as sclerotherapy and surgery have shown limited efficacy in complicated malformations. Most vascular malformations stem from hereditary or somatic mutations akin to oncogenic alterations, activating the PI3K-AKT-mTOR, RAS-MAPK-ERK, and G-protein coupled receptor pathways. Recognizing the parallels with oncogenic mutations, we emphasize the potential of targeted molecular inhibitors in the treatment of vascular malformations by repurposing anticancer drugs. This review delves into the recent development and future use of such agents for the management of slow- and fast-flow vascular malformations, including in more specific situations, such as prenatal treatment and the management of associated coagulopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium. Electronic address: https://twitter.com/emmanuelseront.
- Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium; Institut Roi Albert II, Division of Hematology, Cliniques universitai…
- Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium; Division of Plastic Surgery, Cliniques universitaires Saint-Luc, Univ…
- Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium; Deprtment of Human Molecular Genetics, de Duve Institute, University…
Förderung
- King Baudouin Foundation
- WELBIO
- FRS-FNRS
- Waalse Gewest
- Swiss National Science Foundation
Zitieren
APA
Seront, E., Hermans, C., Boon, L. M., & Vikkula, M. (2024). Targeted treatments for vascular malformations: current state of the art. Journal of Thrombosis and Haemostasis, 22(11), 2961-2975. https://doi.org/10.1016/j.jtha.2024.07.013
Vancouver
Seront E, Hermans C, Boon LM, Vikkula M. Targeted treatments for vascular malformations: current state of the art. Journal of Thrombosis and Haemostasis. 2024;22(11):2961-2975. doi:10.1016/j.jtha.2024.07.013
BibTeX
@article{Seront2024,
author = {Seront, Emmanuel and Hermans, Cedric and Boon, Laurence M and Vikkula, Miikka},
title = {Targeted treatments for vascular malformations: current state of the art},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
volume = {22},
number = {11},
pages = {2961--2975},
doi = {10.1016/j.jtha.2024.07.013}
}
EUVIMED